Piramal Pharma Solutions picks up Indian peptide API maker in push into oncology, metabolic contract work
Peptide therapeutics have been a hot area for investment in recent years, and contract manufacturing players are ramping up capacity to meet growing demand. India’s Piramal Pharma Solutions, fresh off a major cash infusion last summer, is now absorbing a specialized API player to help expand its offerings there.
India’s Piramal will dole out $106 million plus future milestones for Hemmo Pharmaceuticals, which the CDMO called “one of the few pure-play synthetic peptide API manufacturers in the global marketplace,” as part of a bigger push into contract work in oncology and metabolic therapies, the companies said Wednesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 106,500+ biopharma pros reading Endpoints daily — and it's free.